Current Cancer Therapy Reviews最新文献

{"title":"Effects of Vitamins E and D on Mechanical Properties of Breast Cancerous Cells","authors":"Armin Jarahi Khameneh, Dornaz Milani, Nasibeh Babaei, Negin Hannani, Ashkan Heydarian, Hossein Sahbafar","doi":"10.2174/0115733947265982230929154843","DOIUrl":"https://doi.org/10.2174/0115733947265982230929154843","url":null,"abstract":"aims: . This research aims to determine the short-term impact of vitamin D and E on the mechanical properties of breast cancer cells before comparing them with normal breast cells. background: Several investigations have demonstrated that vitamins can be used to treat or prevent cancer by altering actin filaments, inhibiting cell migration and cancer cell proliferation. Vitamins D and E are fat-soluble objective: MCF-7 breast cancer cells, and MCF-7 breast cancer cells method: Atomic force microscopy (AFM) was used to examine the deformation of MCF-10 normal breast cells, MCF-7 breast cancer cells, and MCF-7 breast cancer cells treated with 0.03 μM vitamin D and 16 μM vitamin E solutions. Young's modulus was calculated employing the Hertz model to determine cell stiffness. result: The Young's modulus of vitamin D-treated cancer cells (585.8 Pa) was substantially similar to that of normal cells (455.6 Pa). Nevertheless, vitamin E treatment had no effect on Young's modulus of cancer cells, which remained remarkably similar to that of untreated cancer cells (216.6 and 203.4 Pa, respectively). conclusion: Despite vitamin E, vitamin D enhances the stiffness of tumor cells and makes their mechanical properties similar to normal cells by interfering with actin filaments and cell skeletons, which may inhibit tumor cell migration. other: According to these findings, vitamin D appears to be an effective drug for cancer treatment.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136357859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Streptomyces Paradigm in Anticancer Therapy: A State-of-the Art Review","authors":"Yashendra Sethi, Vidhi Vora, Onyekachi Emmanuel Anyagwa, Nafisa Turabi, Maya Abdelwahab, Oroshay Kaiwan, Hitesh Chopra, Mohamed S. Attia, Galal Yahya, Talha Bin Emran, Inderbir Padda","doi":"10.2174/0115733947254550230920170230","DOIUrl":"https://doi.org/10.2174/0115733947254550230920170230","url":null,"abstract":"Abstract: Cancer is one of the biggest threats to human health with a global incidence of 23.6 million, mortality of 10 million, and an estimated 250 million lost in disability-adjusted life years (DALYs) each year. Moreover, the incidence, mortality, and DALYs have increased over the past decade by 26.3%, 20.9%, and 16.0%, respectively. Despite significant evolutions in medical therapy and advances in the DNA microarray, proteomics technology, and targeted therapies, anticancer drug resistance continues to be a growing concern and invites regular discovery of potent agents. One such agent is the microbe-producing bioactive compounds like Streptomyces, which are proving increasingly resourceful in anticancer therapy of the future. Streptomyces, especially the species living in extreme conditions, produce bioactive compounds with cytolytic and anti-oxidative activity which can be utilized for producing anticancer and chemo-preventive agents. The efficacy of the derived compounds has been proven on cell lines and some of these have already established clinical results. These compounds can potentially be utilized in the treatment of a variety of cancers including but not limited to colon, lung, breast, GI tract, cervix, and skin cancer. The Streptomyces, thus possess the armory to fuel the anticancer agents of the future and help address the problem of rising resistance to currently available anti-cancer drugs. We conducted a state-of-art review using electronic databases of PubMed, Scopus, and Google scholar with an objective to appraise the currently available literature on Streptomyces as a source of anti-cancer agents and to compile the clinically significant literature to update the clinicians.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"93 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136359920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Effects of Bromelain against Colorectal Cancer: A Systematic Review","authors":"Mojgan Forootan, Mehdi Mohammadian Amiri, Mohammad Darvishi, Catherine MT Sherwin, Koruosh Ghanadi","doi":"10.2174/0115733947253563230922092456","DOIUrl":"https://doi.org/10.2174/0115733947253563230922092456","url":null,"abstract":"Background: Colorectal cancer (CRC) is one of the most prevalent cancers worldwide. Objective: Considering the side effects of chemotherapy treatments, we reviewed the anti-cancer effects and mechanisms of bromelain on colon cancer cells in this study. Methods: The PRISMA guidelines were followed in the design of this systematic review. Various databases, including PubMed, Web of Science, Cochrane Library, and Scopus, were thoroughly searched. Finally, 14 articles were retrieved after considering the study's inclusion and exclusion criteria. The desired data were extracted, entered into an Excel file, and the study results were reviewed. Results: According to the included studies, bromelain can significantly reduce the survival and death of cloned cancer cells through different mechanisms. These mechanisms include impeding tumor growth and metastasis by reducing mucins production/secretion and increasing/reducing reactive oxygen species (ROS) production. Moreover, bromelain induces apoptosis via reduced expression of Bcl-2, extracellular signal-related kinase (ERK), Akt, activation caspase system (caspase-3, 7, 8, and 9), and extranuclear p53. Ferroptosis was another mechanism of causing cell death. In addition, bromelain activates the autophagy pathway, lysosome formation, and deregulation of other autophagyrelated proteins. Conclusion: Bromelain effectively inhibits colon cancer cells' growth, proliferation, and metastasis and reduces their survival by different mechanisms. Therefore, after examining clinical studies, it can be used as an effective drug for treating CRC.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136359921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Potential Lead Compounds against BCL-2 through in-silico Screening of Phytochemicals of Nigella sativa and Cuscuta reflexa for Oral Squamous Cell Carcinoma Management","authors":"N. Fazulu Nisa Begum, Pratibha Ramani, Mukesh Doble, Abilasha Ramasubramanian","doi":"10.2174/0115733947249560231003111214","DOIUrl":"https://doi.org/10.2174/0115733947249560231003111214","url":null,"abstract":"Significance of the study: The present study has attempted to assess Bcl2 the efficacy of combination of the Nigella sativa and Cuscuta reflexa to target BCL-2 for anticancer treatment through computer aided drug designing approach.Insilico analysis is frequently used in physicochemical characterisation, the discovery and improvement of novel compounds with affinity to a target, and the elucidation of absorption, distribution, metabolism, excretion, and toxicity features. Aim: The aim of this study is to assess the efficacy of Nigella sativa and Cuscuta reflexa in targeting Bcl2-antiapoptotic protein in Oral Squamous Cell Carcinoma through Insilico analysis. Materials and Methods: The present study was designed to formulate a drug against Oral Squamous cell carcinoma against the target protein Bcl-2. Protein Database (PDB) was used to select and analyse the protein. Based on the literature search, the original molecules selected were thymoquinone, tannin pyrogallol, Cuscutin, kaempferol, nigellicine and the ligand structures were obtained ZINC15 database. Target protein structure was recognised through Protein sequence from PB (Protein Data Bank). Swiss ADME was used for assessing the properties of the molecules. Twenty new molecules were identified from zinc pharmer and docking was done for all the 20 using Swiss dock. Binding energy was assessed and compared with the original molecules.ZINC73690300 and ZINC73690304 had better binding energy than that of original molecules. Both molecules can be potential candidates for Bcl2 inhibition to prevent OSCC. Results: ZINC73690300 and ZINC73690304 had better binding energy than that of the original molecules. Both molecules can be potential candidates for Bcl-2 inhibition to prevent OSCC. Conclusion: The present study evaluated the binding energy and bioavailability of the combined extract, thus attempting to predict the target ligand binding between the compounds in OSCC before attempting in vitro studies.-","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"58 2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136358494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Narrative Testimony and Characteristics of Rottlerin for the Treatment of Various Kinds of Cancer","authors":"Lopamudra Mishra, Lakshmi Kumari, Preeti Patel, Amrita Singh, Balak Das Kurmi","doi":"10.2174/0115733947244863230928095352","DOIUrl":"https://doi.org/10.2174/0115733947244863230928095352","url":null,"abstract":"From ancient times until now, scientists have focused on herbal medicaments for treating various diseases. Rottlerin, a potent PKCδ inhibitor, is one of the greatest herbal medications. Over the years, it was identified that rottlerin has several cellular and molecular targets that could be involved in the fight against cancer. The past and present research has clearly shown that rottlerin inhibits the transcription factors, enzymes, and signaling molecules that regulate the death and life of cancer cells. Although the anticancer property of rottlerin has primarily been attributed to the induction of autophagy and apoptosis, current research has revealed the existence of different damage pathways. The major part described in this mini-review is the antitumor/anticancer effects of rottlerin in various organs of the human body affected by breast cancer, pancreatic cell cancer, bladder cancer, NSCLC, prostate cancer, ovarian cancer, nasopharyngeal cancer, etc.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135198288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systemic Review on Photodynamic Therapy: Emerging Technology with Healing Process","authors":"Prachi varshney, Yogesh Kumar, Devdhar Yadav, Amit Singh, Naga Rani Kagithala, Pramod Kumar Sharma, Omji Porwal, Neeraj Kumar Fuloria, Pradeep Kumar Sharma, Ashok Kumar Gupta, GSN Koteswara Rao","doi":"10.2174/0115733947263042230920040145","DOIUrl":"https://doi.org/10.2174/0115733947263042230920040145","url":null,"abstract":"Abstract: Photodynamic therapy (PDT) is a non-invasive treatment of cancer patients who take a photosensitizer and expose their tumours to light after administering it topically or intravenously. Understanding apoptosis under oxidative conditions makes PDT a more effective treatment. Tissue oxygen, tumour-selective photosensitizer dyes, and customised lighting are needed to create fatal reactive oxygen species (ROS) in cancer. PDT has decreased morbidity and improved survival and status of life when used in combination with other treatments, especially in early-stage malignant tumours. Using interstitial light delivery, PDT can cure large, hidden tumours that would otherwise necessitate extensive surgery. This overview describes the foundational historical work that has shaped the technique since the early 1900s. PDT's efficacy is also increased by innovative photosensitizers and tweaks that increase tumour selectivity. Adverse effects and treatment during therapy, as well as innovative PDT-based applications, are explored in this review. Finally, PDT research gaps and clinical trials have been identified as potential issues.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135546038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Treatment of Lung Cancer using Nanomaterials: Prospective and Advances","authors":"Gupta Swati Sanjay kumar","doi":"10.2174/0115733947250534230922051549","DOIUrl":"https://doi.org/10.2174/0115733947250534230922051549","url":null,"abstract":"Background: Lung cancer is the second most lethal type of cancer, with a poor survival rate of 5 years. It is one of those malignant tumors that has grown most rapidly in the context of mortality and morbidity. Aim: This review article aims to provide insight into current nanotechnological approaches taken into consideration that provide advantages over conventional chemotherapy. Result and Discussion: After comparing conventional chemotherapy and nanotechnology-based therapies for lung cancer, the results showed that recent advances in nanomaterials proved to be more effective in lung cancer diagnosis, mitigation and treatment. Here, Surface-engineered smart nanocarrier-based inhalations, Bio-nanocarriers for lung cancer, gas plasma nanoparticles, and magnetic nanoparticles are discussed. Conclusion: After summarizing these nanomaterials, investigators concluded that the in-vivo and invitro effectiveness of recently developed nanoparticles was found to be better than that of conventional nanoparticles.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135647197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating MiR-1185¸ MiR-3183, and MiR-584 Levels in Plasma as Diagnostic Non-invasive Biomarkers for Early Detection of Breast Cancer","authors":"Abolfazl Khalafi-Nezhad, Ahmad Abdollahi, Mahdi Barazesh, Marzieh Amani, Setare Motazedi, Vahid Ebrahimi, Ali Zarei","doi":"10.2174/1573394719666230915103139","DOIUrl":"https://doi.org/10.2174/1573394719666230915103139","url":null,"abstract":"Introduction: MicroRNAs (miRNAs) are non-coding RNA molecules with short sequences that function as main post-transcriptional gene regulators of different biological pathways via negative regulation of gene expression, thereby leading to either mRNA degradation or translational blockade. Dysregulated expression of these miRNAs has been related etiologically to many human diseases, including breast cancer. Various cellular processes of breast cancer progression, including cell proliferation, apoptosis, metastasis, recurrence and chemodrug resistance, are modulated by oncogenic miRNA (oncomiR). Objective: The objective of this investigation was to study the expression level and potential diagnostic/prognostic roles of circulating microRNAs (miR-3183, miR-1185, and miR-584) as novel breast cancer biomarkers. Method: The current study was conducted on 99 breast cancer (BC) female patients, aged between 20-63 years old, as the case group and 50 age-matched healthy females as control (HC). After microRNA extraction from the serum samples, real-time PCR was carried out for relative expression quantification of miR-1185, miR-3183a, and miR-584. The ROC curve analysis was performed to investigate the diagnostic value of miRNAs. Result: It was demonstrated that miRNA-1185, miRNA-584, and miRNA-3183 were significantly up-regulated (p-values <0.0001) in female BC cases compared to the control group. Besides, based on the ROC analysis for BC versus HC, it was revealed that the AUC for miRNA-584 was 0.844 (95% confidence interval (CI) and could be proposed as a diagnostic biomarker for breast cancer screening and follow-up. Conclusion: MiRNAs expression profiling using blood-based samples demonstrated their upregulation in the serum and plasma and revealed the concept that circulating miRNAs have high potential as novel noninvasive biomarkers for cancer diagnosis and screening.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current perspectives of matrix metalloproteinase 11 (MMP11) as a diagnostic and therapeutic target for cancer","authors":"Asokan Shobana, Remella Venkata Deeksha, Syed Ali Abdul Rahman, Tiviya Thangaswamy, Revathi Paramasivam Oviya, Gopisetty Gopal","doi":"10.2174/1573394719666230914103330","DOIUrl":"https://doi.org/10.2174/1573394719666230914103330","url":null,"abstract":"Abstract: Matrix metalloproteinase 11 (MMP11), also known as stromelysin-3, is a member of the matrix metalloproteinases family of proteins that are involved in physiological and pathological extracellular matrix remodelling. MMP11 does not hydrolyse classical MMP substrates, such as laminin and fibronectin, and many of its substrates remain unknown, piquing the interest of researchers. Several studies have reported the role of MMP11 in inducing tumour growth by inhibiting apoptosis and promoting cancer cell migration and invasion. Various reports have shown its potential as a diagnostic and prognostic marker in a majority of cancers. MMP11 also induces an immune response as a tumour-associated antigen, and recent evidence shows the involvement of many microRNAs in targeting MMP11 in cancer, with prospective future applications in cancer immunotherapy and gene silencing. Owing to the importance of MMP11 in both cancer diagnosis and therapy, there is a need for deeper understanding of its mechanism and role in tumour progression. The current review focuses on the role of MMP11 in cell signalling pathways, its expression status in various cancers, and its potential in cancer treatment.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"216 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134970676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aptamer-guided Selective Delivery of Therapeutics to Breast Cancer Cells Expressing Specific Biomarkers","authors":"Swaroop Kumar Pandey, Mradula Parul, Manikandan Santhanam","doi":"10.2174/1573394719666230911113126","DOIUrl":"https://doi.org/10.2174/1573394719666230911113126","url":null,"abstract":"Abstract: Cancer biomarkers or tumor-associated antigens (TAA) are the focus area of current research in cancer biology for diagnosis, prognosis, screening, and targeted treatments. Breast cancer is the second most common type of cancer, affecting women more than men. Conventional methods and antibody-targeted therapies are less effective and suffer systemic cytotoxicity, poor tissue sensitivity, low penetration capacity, and reduced accumulation of the drug in tumor cells that limit its application and sometimes result in treatment failure. Opting for aptamer-mediated targeted delivery of various anti-cancer agents (drugs, siRNA, miRNA, shRNA and peptides) could possibly overcome these limitations by utilizing aptamer as a targeting ligand. The purpose of this article is to review the novel indicative biomarkers of breast cancer and also describe current applications of aptamer-guided active targeting systems in breast cancer therapy in vivo and in vitro.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135981349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}